Velpatasvir

The standard adult dosage for Velpatasvir, when used as part of the most common fixed-dose combination (sofosbuvir/velpatasvir), is 100 mg once daily. This is almost always paired with 400 mg of sofosbuvir in a single tablet.

For patients with compensated liver disease (Child-Pugh A), the typical duration of treatment is 12 weeks. In patients with decompensated cirrhosis (Child-Pugh B or C), the 100 mg daily dose of Velpatasvir is maintained, but it is typically co-administered with ribavirin for a 12-week duration. Your healthcare provider will determine the exact regimen based on your liver function and viral genotype.

Velpatasvir is approved for use in pediatric patients aged 3 years and older. The dosage is strictly based on the child's body weight to ensure safety and efficacy:

• Weight ≥ 30 kg: One 100 mg/400 mg tablet once daily.
• Weight 17 kg to < 30 kg: One 50 mg/200 mg tablet (or equivalent pellets) once daily.
• Weight < 17 kg: One 25 mg/100 mg pellet packet once daily.

Clinical data from pediatric trials suggest that the safety profile in children is similar to that in adults. However, adherence is critical in this population to prevent the development of viral resistance.

Renal Impairment

For patients with mild to moderate renal impairment, no dosage adjustment of Velpatasvir is required. In patients with severe renal impairment (estimated Glomerular Filtration Rate [eGFR] < 30 mL/min/1.73 m²) or end-stage renal disease (ESRD) requiring hemodialysis, the safety of Velpatasvir has been established, and no specific dose adjustment of Velpatasvir itself is recommended. However, the partner drugs (like sofosbuvir) must be monitored closely in these populations.

Hepatic Impairment

No dosage adjustment of Velpatasvir is required for patients with mild, moderate, or severe hepatic impairment (Child-Pugh A, B, or C). In patients with decompensated cirrhosis, the clinical focus shifts to the addition of ribavirin rather than adjusting the Velpatasvir dose.

Elderly Patients

Clinical studies of Velpatasvir did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Velpatasvir should be taken exactly as prescribed by your doctor. To ensure the best results:

• Consistency: Take your dose at the same time every day. This maintains a steady level of the drug in your bloodstream to fight the virus.
• With or Without Food: Velpatasvir can be taken with or without food. However, taking it with food may help if you experience nausea.
• Swallow Whole: Tablets should be swallowed whole. Do not chew, crush, or break the tablets, as this can affect how the drug is absorbed. For children using pellets, follow the specific instructions for mixing with non-acidic soft food (like pudding or ice cream) and consume within 15 minutes.
• Acid Management: If you take antacids, take them 4 hours before or 4 hours after Velpatasvir. If you take H2 blockers (like famotidine), take them at the same time as Velpatasvir or 12 hours apart.
• Storage: Store the medication at room temperature, away from moisture and heat.

If you miss a dose of Velpatasvir, take it as soon as you remember on the same day. If it is nearly time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take two doses at once to make up for a missed one. Maintaining a consistent level of medication is vital for curing Hepatitis C.

There is no specific antidote for a Velpatasvir overdose. In the event of an overdose, patients should be monitored for evidence of toxicity. Treatment consists of general supportive measures, including monitoring of vital signs and observation of the patient's clinical status. If you suspect an overdose, contact your local poison control center or seek emergency medical attention immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop the medication without medical guidance, as this can cause the virus to become resistant to treatment.

Because Velpatasvir is administered in combination with other drugs, side effects are often a result of the combined regimen. According to clinical trial data (specifically the ASTRAL trials), the most frequently reported side effects occurring in more than 10% of patients include:

• Headache: This is the most common complaint. It is usually mild to moderate and tends to diminish as the body adjusts to the medication. Patients describe it as a dull pressure or tension-type headache.
• Fatigue: Many patients report feeling unusually tired or lacking energy during the first few weeks of treatment. This is often manageable with adequate rest and hydration.
• Nausea: Some patients experience a queasy feeling after taking the dose. Taking the medication with a small meal can often mitigate this effect.
• Insomnia: Difficulty falling or staying asleep has been reported. This may be linked to the body's systemic response to the viral clearance process.

These effects are less frequent but may still occur during the 12-week treatment course:

• Diarrhea: Loose stools or increased frequency of bowel movements.
• Anemia: A decrease in red blood cell counts, particularly when Velpatasvir is used with ribavirin in patients with cirrhosis.
• Rash: Mild skin irritation or redness may occur.
• Increased Lipase: Asymptomatic elevations in lipase (an enzyme that breaks down fats) may be seen in blood tests, though clinical pancreatitis is rare.

• Depression or Mood Changes: While rare, some patients may experience shifts in mood, anxiety, or depressive symptoms. This requires immediate discussion with a healthcare provider.
• Photosensitivity: Increased sensitivity of the skin to sunlight, leading to easier sunburn.

> Warning: Stop taking Velpatasvir and call your doctor immediately if you experience any of these serious symptoms.

1. 1Hepatitis B Reactivation: If you have ever had Hepatitis B, Velpatasvir can cause the virus to become active again. Symptoms include yellowing of the skin/eyes (jaundice), dark urine, and severe right-sided abdominal pain.
2. 2Severe Bradycardia (Slow Heart Rate): This is a critical risk if Velpatasvir is taken with the heart medication amiodarone. Symptoms include fainting, dizziness, shortness of breath, and chest pain.
3. 3Severe Allergic Reaction (Anaphylaxis): Signs include swelling of the face, lips, or tongue; difficulty breathing; or a widespread, blistering rash.
4. 4Significant Cognitive Impairment: Confusion, extreme memory lapses, or difficulty concentrating beyond what is expected from mild fatigue.

Velpatasvir is typically taken for a short duration (12 to 24 weeks). Therefore, long-term side effects from the drug itself are not well-documented. However, the long-term benefits are significant, including a reduced risk of liver cancer (hepatocellular carcinoma) and liver failure due to the clearance of the HCV virus. Some studies have suggested that clearing HCV can lead to changes in glucose metabolism, so patients with diabetes should monitor their blood sugar closely as it may drop during or after treatment.

Velpatasvir-containing products carry a FDA Boxed Warning regarding the risk of Hepatitis B Virus (HBV) Reactivation.

Full Text Summary: Healthcare providers must test all patients for evidence of current or prior HBV infection before initiating treatment with Velpatasvir. HBV reactivation has been reported in HCV/HBV co-infected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Patients should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up.

Report any unusual symptoms to your healthcare provider immediately. Your doctor will perform regular blood tests to monitor your liver function and viral levels throughout the treatment process.

Velpatasvir is a highly effective medication, but it must be used with caution in certain clinical contexts. The most important safety consideration is the status of other viral infections, specifically Hepatitis B. Because Velpatasvir rapidly reduces the Hepatitis C viral load, it can allow the Hepatitis B virus to replicate uncontrollably if a co-infection exists. This can lead to sudden and severe liver damage.

Additionally, Velpatasvir has significant interactions with many common medications. It is vital that you provide your healthcare provider with a complete list of all prescription drugs, over-the-counter medications, vitamins, and herbal supplements you are taking.

Risk of Hepatitis B Virus Reactivation in Patients Co-infected with HCV and HBV.

As detailed in the side effects section, the FDA requires a boxed warning because the use of direct-acting antivirals like Velpatasvir can trigger a reactivation of Hepatitis B. This can occur during or after the treatment course. Doctors must screen for HBV before starting Velpatasvir and monitor co-infected patients closely.

• Bradycardia Risk with Amiodarone: There is a severe risk of symptomatic bradycardia (dangerously slow heart rate) when Velpatasvir (in combination with sofosbuvir) is taken with amiodarone, a medication used for heart rhythm disorders. This combination is generally not recommended. If it must be used, inpatient cardiac monitoring for the first 48 hours is often required.
• Acid-Reducing Agents: Because Velpatasvir requires an acidic environment in the stomach to be absorbed, the use of Proton Pump Inhibitors (PPIs) like omeprazole can make the treatment less effective. Patients should discuss alternative acid management strategies with their doctor.
• Diabetes Management: Clearing the Hepatitis C virus may improve glucose metabolism. Patients with diabetes may experience hypoglycemia (low blood sugar) if their diabetes medications are not adjusted during treatment.
• Warfarin Monitoring: For patients taking warfarin (a blood thinner), the international normalized ratio (INR) may fluctuate as liver function improves during treatment. Close monitoring of the INR is essential.

Before and during treatment, your healthcare provider will require several laboratory tests:

1. 1HBV Screening: HBsAg and Anti-HBc tests to check for Hepatitis B.
2. 2HCV RNA: To measure the amount of Hepatitis C virus in your blood at the start, potentially during, and 12 weeks after treatment.
3. 3Liver Function Tests (LFTs): To monitor enzymes like ALT and AST, which indicate liver inflammation.
4. 4Renal Function: Monitoring eGFR to ensure the kidneys are processing the medication safely.

Velpatasvir itself is not known to cause significant impairment in the ability to drive or operate machinery. However, because fatigue and headache are common side effects, patients should assess their individual reaction to the medication before engaging in potentially dangerous activities.

While there is no direct chemical interaction between Velpatasvir and alcohol, patients with chronic Hepatitis C are strongly advised to avoid alcohol. Alcohol accelerates liver scarring (fibrosis) and increases the risk of liver cancer, directly counteracting the benefits of the antiviral treatment.

Treatment with Velpatasvir should not be stopped prematurely. Discontinuing the drug before the full 12 or 24-week course is completed significantly increases the risk that the virus will return and develop resistance to future treatments. There is no 'withdrawal syndrome' associated with Velpatasvir, but the medical consequence of failure to cure the infection is severe.

> Important: Discuss all your medical conditions, especially heart rhythm problems and previous Hepatitis B infection, with your healthcare provider before starting Velpatasvir.

Velpatasvir must never be used with potent inducers of CYP2B6, CYP2C8, or CYP3A4, as these drugs will drastically reduce the levels of Velpatasvir in the blood, leading to treatment failure and viral resistance.

• Rifampin and Rifabutin: Used for tuberculosis; these will make Velpatasvir ineffective.
• St. John’s Wort: An herbal supplement for depression that significantly induces metabolic enzymes.
• Carbamazepine, Phenytoin, and Phenobarbital: Anticonvulsants used for seizures.

• Amiodarone: Co-administration can lead to life-threatening slow heart rate. If no other treatment options exist, cardiac monitoring is mandatory.
• Digoxin: Velpatasvir can increase levels of digoxin, potentially leading to digoxin toxicity. Your doctor will monitor digoxin blood levels.
• Tenofovir Disoproxil Fumarate (TDF): Velpatasvir can increase the levels of tenofovir (used for HIV), which may increase the risk of kidney toxicity. Renal function must be monitored closely.
• Statins (e.g., Rosuvastatin, Atorvastatin): Velpatasvir inhibits the transporters (BCRP and OATP) that move statins into the liver. This can significantly increase statin levels in the blood, increasing the risk of muscle damage (rhabdomyolysis). Statin doses may need to be lowered.

• Topotecan: Levels may be increased by Velpatasvir; monitoring for bone marrow suppression is required.
• Warfarin: Changes in liver function during HCV treatment can change how warfarin works. Frequent INR monitoring is necessary.
• Efavirenz: This HIV medication can decrease Velpatasvir levels. The combination is generally avoided.

There are no major food restrictions for Velpatasvir. It can be taken with or without food. However, as mentioned previously, the absorption is highly dependent on stomach acid. Avoid consuming large amounts of alkaline water or excessive amounts of dairy immediately around the time of dosing if you are also using acid-reducing medications.

• St. John’s Wort: As noted, this is strictly contraindicated.
• Milk Thistle: While often used by patients with liver disease, milk thistle can theoretically interfere with some metabolic pathways, though no severe interactions have been documented. Always inform your doctor.
• Antacids (Calcium Carbonate, Magnesium Hydroxide): These must be separated from the Velpatasvir dose by at least 4 hours.

Velpatasvir does not typically interfere with standard laboratory assays (like glucose or electrolytes). However, it will cause a rapid decline in HCV RNA levels, which is the intended effect. It may also cause transient elevations in bilirubin or lipase that do not necessarily indicate organ damage but should be interpreted by a specialist.

For each major interaction, the primary mechanism is usually transporter inhibition (specifically P-gp and BCRP) or enzymatic induction (CYP enzymes). The clinical consequence is either increased toxicity of the co-administered drug or reduced efficacy of Velpatasvir.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Do not start any new medication during your 12-week treatment course without consulting your hepatologist.

Velpatasvir is contraindicated in patients with a known hypersensitivity (severe allergy) to the drug or any of its excipients. An absolute contraindication also exists for the co-administration of Velpatasvir with drugs that are potent inducers of P-glycoprotein (P-gp) or specific Cytochrome P450 enzymes (CYP2B6, CYP2C8, CYP3A4).

• Potent CYP/P-gp Inducers: Drugs like Rifampin or St. John's Wort induce the production of enzymes and transporters that clear Velpatasvir from the body. This is an absolute contraindication because it virtually guarantees the treatment will fail, which is a significant public health concern as it can foster drug-resistant strains of Hepatitis C.

• Severe Bradycardia Risk: While not an absolute contraindication in the strictest sense, the use of Velpatasvir with amiodarone is so dangerous that it is avoided unless no other options exist. The mechanism involves an unknown synergistic effect on the sinoatrial node of the heart.
• Severe Renal Impairment: Historically, there were concerns regarding the sofosbuvir component used with Velpatasvir in patients with an eGFR < 30. While recent data suggests it is safe, it remains a relative contraindication requiring expert specialist oversight.
• Decompensated Cirrhosis (without Ribavirin): Velpatasvir should not be used alone (or only with sofosbuvir) in Child-Pugh B or C patients; it must be used with ribavirin to ensure efficacy. Using it without ribavirin in this population is considered a sub-optimal treatment contraindication.

Patients who have had a severe allergic reaction to other NS5A inhibitors (such as Ledipasvir or Daclatasvir) should be treated with extreme caution, as there is a theoretical risk of cross-sensitivity due to the similar chemical structures of these molecules. Signs of cross-sensitivity include hives, difficulty breathing, or swelling of the throat.

> Important: Your healthcare provider will evaluate your complete medical history and current medication list to ensure no contraindications exist before prescribing Velpatasvir.

Velpatasvir is classified as a drug where human data is limited. In animal reproduction studies (rats and rabbits), no adverse developmental outcomes were observed at exposures significantly higher than the human therapeutic dose. However, Velpatasvir is almost always used with Sofosbuvir, and sometimes with Ribavirin.

• Ribavirin Warning: If Velpatasvir is used with ribavirin, it is strictly contraindicated in pregnant women and in the male partners of pregnant women due to ribavirin's known teratogenic (causing birth defects) and embryocidal effects.
• Contraception: Women of childbearing potential must have a negative pregnancy test before starting treatment and must use effective contraception during treatment.

It is not known whether Velpatasvir is present in human breast milk. In animal studies, Velpatasvir was detected in the milk of lactating rats with no adverse effects on the nursing pups. Because many drugs are excreted in human milk, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Velpatasvir and any potential adverse effects on the breastfed child from the drug or the underlying maternal condition.

Velpatasvir is FDA-approved for pediatric patients 3 years of age and older. The safety and efficacy in children younger than 3 years have not been established. In clinical trials of children aged 3 to 17, the SVR (cure) rates were comparable to those seen in adults. Dosing must be carefully calculated based on weight, and parents must ensure strict adherence to the daily schedule to prevent treatment failure.

Clinical trials included a portion of patients over age 65. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. However, elderly patients are more likely to have reduced renal or hepatic function and are often on multiple medications (polypharmacy), which increases the risk of drug-drug interactions. Special attention should be paid to the use of statins and blood pressure medications in this age group.

For patients with mild to moderate renal impairment, no dose adjustment is needed. In patients with ESRD or severe renal impairment, Velpatasvir is considered safe, but the overall regimen must be managed by a specialist, as the accumulation of metabolites from partner drugs (like sofosbuvir) requires monitoring. Dialysis does not significantly remove Velpatasvir from the blood because it is highly protein-bound.

No dose adjustment is required for patients with any degree of hepatic impairment (Child-Pugh A, B, or C). Velpatasvir has been specifically studied in patients with decompensated cirrhosis and has shown a favorable safety profile when used as directed. However, these patients are at higher risk for complications like hepatic encephalopathy and should be monitored closely by a hepatologist.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.

Velpatasvir is a direct-acting antiviral agent (DAA) that targets the Hepatitis C Virus (HCV) NS5A protein. NS5A is a non-structural 5A phosphoprotein that is essential for both the replication of the HCV RNA genome and the assembly of viral particles. Velpatasvir binds to the N-terminus within Domain I of the NS5A protein, which is thought to block the protein's function by inducing a conformational change or preventing its dimerization. This disruption prevents the formation of the replication complex and the membranous web, effectively halting the viral lifecycle. Its pangenotypic activity is due to its ability to bind to the conserved regions of NS5A across all six major HCV genotypes.

Velpatasvir shows high potency in cell culture assays against various HCV genotypes, with EC50 values (the concentration required to inhibit 50% of viral replication) in the low picomolar range. There is no evidence of a significant QT prolongation effect at doses up to 5 times the therapeutic dose. The dose-response relationship is well-characterized, with 100 mg providing maximal viral suppression in most patients. Tolerance to the antiviral effect does not develop during the standard 12-week treatment course, provided adherence is maintained.

| Parameter | Value |

|---|---|

| Bioavailability | 25-30% (estimated) |

| Protein Binding | >99.5% (primarily to albumin) |

| Half-life | ~15 hours |

| Tmax | 3 hours |

| Metabolism | CYP2B6, CYP2C8, CYP3A4 (minor) |

| Excretion | Fecal 94%, Renal 0.4% |

• Molecular Formula: C38H40N4O8
• Molecular Weight: 680.76 g/mol
• Solubility: Practically insoluble (<0.1 mg/mL) across the pH range of 3.0 to 7.5, but solubility increases significantly at pH below 2.0.
• Structure: Velpatasvir is a complex tetracyclic molecule featuring a carbamate moiety and multiple chiral centers. Its structure allows for multiple hydrogen-bonding interactions with the NS5A protein.

Velpatasvir is classified as a Hepatitis C Virus NS5A Inhibitor. It is often grouped with other DAAs like Ledipasvir, Elbasvir, and Pibrentasvir. Within the therapeutic area of hepatology, it is considered a cornerstone of pangenotypic therapy, often used in fixed-dose combinations to provide a complete treatment regimen in a single pill.